
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AZACITIDINE | Allergan | N-208216 RX | 2016-04-29 | 1 products |
| ONUREG | Bristol Myers Squibb | N-214120 RX | 2020-09-01 | 2 products, RLD, RS |
| VIDAZA | Bristol Myers Squibb | N-050794 RX | 2004-05-19 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| azacitidine | ANDA | 2025-09-16 |
| azacitidine for | ANDA | 2022-09-14 |
| onureg | New Drug Application | 2022-10-26 |
| vidaza | New Drug Application | 2024-01-29 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myelomonocytic leukemia chronic | — | D015477 | C93.1 |
| sideroblastic anemia | — | D000756 | D64.3 |
| refractory anemia | — | D000753 | D46.4 |
Expiration | Code | ||
|---|---|---|---|
AZACITIDINE, VIDAZA, BRISTOL-MYERS | |||
| 2029-05-20 | ODE-399 | ||
| 2025-05-20 | I-889 | ||
AZACITIDINE, ONUREG, BRISTOL | |||
| 2027-09-01 | ODE-320 | ||
Code | Description |
|---|---|
| J9025 | Injection, azacitidine, 1 mg |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 15 | 26 | 4 | 1 | 5 | 47 |
| Preleukemia | D011289 | — | — | 14 | 23 | 3 | 1 | 3 | 40 |
| Syndrome | D013577 | — | — | 10 | 16 | 2 | 1 | 1 | 28 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 23 | 28 | 4 | — | 2 | 49 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 17 | 27 | 4 | — | 2 | 43 |
| Myeloid leukemia | D007951 | — | C92 | 16 | 20 | 4 | — | 2 | 36 |
| Lymphoma | D008223 | — | C85.9 | 11 | 6 | 2 | — | — | 16 |
| T-cell lymphoma | D016399 | — | — | 1 | 1 | 2 | — | — | 4 |
| T-cell lymphoma peripheral | D016411 | — | — | 1 | 1 | 2 | — | — | 4 |
| Immunoblastic lymphadenopathy | D007119 | EFO_1001350 | C86.5 | 1 | — | 2 | — | — | 3 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | 1 | — | — | 2 |
| Pathologic complete response | D000095384 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 9 | 5 | — | — | — | 12 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 4 | 5 | — | — | 1 | 10 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 1 | — | — | — | 7 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 2 | 5 | — | — | — | 7 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 3 | — | — | — | 6 |
| Hodgkin disease | D006689 | — | C81 | 5 | 1 | — | — | — | 5 |
| Recurrence | D012008 | — | — | 3 | 2 | — | — | — | 5 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 2 | — | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 1 | — | — | — | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 3 | 1 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 4 | — | — | — | 1 | 5 |
| Sarcoma | D012509 | — | — | 2 | — | — | — | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | 1 | 2 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Azacitidine |
| INN | azacitidine |
| Description | 5-azacytidine is an N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia. It has a role as an antineoplastic agent. It is a N-glycosyl-1,3,5-triazine and a nucleoside analogue. It is functionally related to a beta-D-ribose. |
| Classification | Small molecule |
| Drug class | H2-receptor antagonists (cimetidine type) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 |
| PDB | — |
| CAS-ID | 320-67-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1489 |
| ChEBI ID | 2038 |
| PubChem CID | 9444 |
| DrugBank | DB00928 |
| UNII ID | M801H13NRU (ChemIDplus, GSRS) |









